Adipotide

Overview

Adipotide is an experimental peptidomimetic — a synthetic molecule engineered to behave like a peptide — that was designed to selectively target and shrink white adipose (fat) tissue. Rather than acting on appetite or metabolism the way most weight-loss drugs do, it was built to disrupt the blood vessels that supply fat, causing those fat cells to lose their blood supply and die.

The compound emerged from research by Kolonin, Pasqualini, and Arap, who used phage-display screening to identify a peptide sequence that homes to the vasculature of white fat. In animal studies it produced striking weight loss, which drew considerable attention as a potential obesity therapy.

Human evidence, however, is very limited. Adipotide is not approved by any major regulator, its clinical development has been discontinued, and it remains a highly experimental compound sold only for research use.

How it works

Adipotide is a chimeric molecule with two functional parts. A targeting sequence (CKGGRAKDC) binds to prohibitin, a membrane protein that is enriched on the endothelial cells lining blood vessels within white fat. This is intended to concentrate the molecule at fat-tissue vasculature rather than throughout the body.

Once bound and internalized, the second portion — a pro-apoptotic segment, D(KLAKLAK)2 — is thought to disrupt mitochondrial membranes and trigger programmed cell death (apoptosis). In preclinical models this ablated the blood supply to white fat, leading to resorption of the tissue. Because prohibitin is not entirely exclusive to fat vasculature, this targeting is imperfect, which is relevant to the compound’s observed off-target effects.

Reported benefits

• Rapid, substantial weight loss in obese mice and rhesus monkeys (preclinical data)
• Reduction of white adipose tissue via targeted vascular disruption
• Improved insulin sensitivity reported in obese non-human primates

These are effects reported in animal research, not established or approved outcomes in humans.

Considerations & side effects

The most significant concern with Adipotide is kidney toxicity. Its early-phase human study was halted in part over dose-limiting renal side effects, and this nephrotoxicity — likely tied to prohibitin also being present in kidney tissue — is a key reason clinical development was discontinued. Because it works by killing cells, any off-target activity carries meaningful risk.

Given the discontinued development and the absence of controlled human safety data, the long-term risk profile of Adipotide is poorly characterized. Purity and identity of material sold on the research-chemical market vary widely. This is not a substitute for evaluation and treatment by a qualified clinician.